Nine-Month Results Show Continuing Efficacy of Abivax’s ABX464 in Extension Trial

Nine-Month Results Show Continuing Efficacy of Abivax’s ABX464 in Extension Trial
Treatment with Abivax's ABX464 showed continuing effectiveness in ulcerative colitis patients, according to nine-month data of a maintenance clinical trial. The company is now recruiting people with moderate-to-severe ulcerative colitis for its Phase 2b trial (NCT03760003) of ABX464, to be conducted in up to 150 sites in more than 15 countries. ABX464 is a small molecule taken once daily by mouth. It works by targeting a group of proteins called the Cap Binding Complex, a novel mechanism of action for anti-inflammatory therapies. This leads to a series of events within cells, namely the production of microRNA-124 (miR-124). This molecule reduces the production of inflammatory signals, thus "putting the brakes" on inflammation. The treatment was tested in a Phase 2a clinical trial (NCT03093259) in which 32 participants were randomly selected to receive either 50 milligrams of ABX464 or a placebo for eight weeks. A total 29 patients completed the trial, and 35% of those given ABX464 were in clinical remission at the study's end. After this study, all participants had the option to continue in an open-label e
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *